Keeping Track: US FDA Clears New Uses For Incyte’s Pemazyre, AbbVie’s Imbruvica; Minerva Seeks First Negative Symptoms Claim In Schizophrenia
Executive Summary
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker